| Nomenclature | GPR12 | GPR15 | GPR17 | GPR19 |
| HGNC, UniProt | GPR12, P47775 | GPR15, P49685 | GPR17, Q13304 | GPR19, Q15760 |
| Endogenous agonists | – | – | UDP‐glucose (pEC50 5.9–9.5) [130, 344], LTC4 (pEC50 7.8–9.5) [344], UDP‐galactose (pEC50 6–8.9) [130, 344], uridine diphosphate (pEC50 6–8.8) [130, 344], LTD4 (pEC50 8.1–8.4) [344] | – |
| Comments | Reports that sphingosine 1‐phosphate is a ligand of GPR12 [814, 1921] have not been replicated in arrestin‐based assays [1785, 2093]. Gene disruption results in dyslipidemia and obesity [154]. | Reported to act as a co‐receptor for HIV [462]. In an infection‐induced colitis model, Gpr15 knockout mice were more prone to tissue damage and inflammatory cytokine expression [945]. | Reported to be a dual leukotriene and uridine diphosphate receptor [344]. Another group instead proposed that GPR17 functions as a negative regulator of the CysLT1 receptor response to leukotriene D4 (LTD4). For further discussion, see [396]. Reported to antagonize CysLT1 receptor signalling in vivoand in vitro [1175]. See reviews [250] and [396]. | – |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.